Fulcrum Therapeutics Inc (NASDAQ: FULC) kicked off on Tuesday, up 1.84% from the previous trading day, before settling in for the closing price of $3.26. Over the past 52 weeks, FULC has traded in a range of $2.87-$13.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -1.10% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 82.53%. With a float of $52.73 million, this company’s outstanding shares have now reached $61.92 million.
In an organization with 76 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.69%, operating margin of -40.15%, and the pretax margin is -24.79%.
Fulcrum Therapeutics Inc (FULC) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fulcrum Therapeutics Inc is 15.49%, while institutional ownership is 82.07%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Vice President, Finance sold 4,884 for $11.72, making the entire transaction worth $57,219. This insider now owns 11,807 shares in total.
Fulcrum Therapeutics Inc (FULC) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.39 earnings per share (EPS), higher than consensus estimate (set at -0.43) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 82.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.40% during the next five years compared to 1.09% growth over the previous five years of trading.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Take a look at Fulcrum Therapeutics Inc’s (FULC) current performance indicators. Last quarter, stock had a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.62 million. That was inferior than the volume of 0.99 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 44.67%. Additionally, its Average True Range was 0.24.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 6.26%, which indicates a significant decrease from 33.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.44% in the past 14 days, which was lower than the 167.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.57, while its 200-day Moving Average is $7.42. However, in the short run, Fulcrum Therapeutics Inc’s stock first resistance to watch stands at $3.38. Second resistance stands at $3.43. The third major resistance level sits at $3.52. If the price goes on to break the first support level at $3.24, it is likely to go to the next support level at $3.15. Assuming the price breaks the second support level, the third support level stands at $3.10.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
The company with the Market Capitalisation of 207.17 million has total of 62,401K Shares Outstanding. Its annual sales at the moment are 2,810 K in contrast with the sum of -97,340 K annual income. Company’s last quarter sales were recorded 80,000 K and last quarter income was 55,410 K.
